Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China · Delayed Price · Currency is CNY

55.74

+0.20 (0.36%)

At close: Sep 16, 2026

Market Cap	25.93B -24.6%
Revenue (ttm)	968.83M +89.5%
Net Income	-597.06M
EPS	-1.29
Shares Out	465.17M
PE Ratio	n/a
Forward PE	20.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,526,857
Open	55.10
Previous Close	55.54
Day's Range	55.10 - 56.50
52-Week Range	35.73 - 76.50
Beta	-0.01
Analysts	Buy
Price Target	83.00 (+48.91%)
Earnings Date	Aug 21, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., L... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2017

Employees 990

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688192

Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 688192 stock is "Buy." The 12-month stock price target is ¥83.00, which is an increase of 48.91% from the latest price.

Price Target

¥83.00

(48.91% upside)

Analyst Consensus: Buy

Stock Forecasts